Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-DM101
- Development stage
- Phase 1
- Lead developer
- Development Center for Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DCB-DM101 is a botanical investigational drug developed by the Development Centre for Biotechnology (DCB) in Taiwan. It is being studied as an add-on oral treatment for patients with type 2 diabetes mellitus (T2DM) who have inadequately controlled glucose levels despite standard antidiabetic therapies. The drug is administered orally and has been evaluated in phase 1 clinical trials to assess its safety and efficacy when combined with existing treatments such as metformin, sitagliptin, or empagliflozin. The precise mechanism of action of DCB-DM101 remains unknown[1][2][3].
- Other names
- Phellodendron amurense extract
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on DCB-DM101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-DM101.